- Home
- GDTC vs APVO Comparison
GDTC vs APVO Comparison
Compare GDTC & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- APVO
- Stock Information
- Founded
- GDTC 2018
- APVO 2016
- Country
- GDTC Singapore
- APVO United States
- Employees
- GDTC N/A
- APVO N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- APVO Health Care
- Exchange
- GDTC Nasdaq
- APVO Nasdaq
- Market Cap
- GDTC 24.2M
- APVO 21.7M
- IPO Year
- GDTC 2023
- APVO N/A
- Fundamental
- Price
- GDTC $2.28
- APVO $1.58
- Analyst Decision
- GDTC Buy
- APVO
- Analyst Count
- GDTC 1
- APVO 0
- Target Price
- GDTC $5.00
- APVO N/A
- AVG Volume (30 Days)
- GDTC 105.3K
- APVO 4.9M
- Earning Date
- GDTC 01-01-0001
- APVO 11-06-2025
- Dividend Yield
- GDTC N/A
- APVO N/A
- EPS Growth
- GDTC N/A
- APVO N/A
- EPS
- GDTC N/A
- APVO N/A
- Revenue
- GDTC $573,193.00
- APVO N/A
- Revenue This Year
- GDTC $5.37
- APVO N/A
- Revenue Next Year
- GDTC N/A
- APVO N/A
- P/E Ratio
- GDTC N/A
- APVO N/A
- Revenue Growth
- GDTC 63.03
- APVO N/A
- 52 Week Low
- GDTC $1.65
- APVO $1.32
- 52 Week High
- GDTC $4.05
- APVO $381.10
- Technical
- Relative Strength Index (RSI)
- GDTC 61.26
- APVO 46.60
- Support Level
- GDTC $1.95
- APVO $1.50
- Resistance Level
- GDTC $2.43
- APVO $1.67
- Average True Range (ATR)
- GDTC 0.18
- APVO 0.13
- MACD
- GDTC 0.02
- APVO 0.02
- Stochastic Oscillator
- GDTC 71.00
- APVO 32.12
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.